uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab
Odense Univ Hosp, Dept Oncol, DK-5000 Odense, Denmark.;Univ Southern Denmark, Inst Clin Res, Odense, Denmark..
Rigshosp, Finsen Lab, DK-2100 Copenhagen, Denmark.;Univ Copenhagen, Biotech Res & Innovat Ctr BRIC, DK-1168 Copenhagen, Denmark..
Rigshosp, Finsen Lab, DK-2100 Copenhagen, Denmark.;Univ Copenhagen, Biotech Res & Innovat Ctr BRIC, DK-1168 Copenhagen, Denmark..
Rigshosp, Finsen Lab, DK-2100 Copenhagen, Denmark.;Univ Copenhagen, Biotech Res & Innovat Ctr BRIC, DK-1168 Copenhagen, Denmark..
Show others and affiliations
2015 (English)In: International Journal of Cancer, ISSN 0020-7136, E-ISSN 1097-0215, Vol. 137, no 10, 2470-2477 p.Article in journal (Refereed) Published
Abstract [en]

Circulating forms of the urokinase plasminogen activator receptor (uPAR) are associated with prognosis in patients with colorectal cancer. Preclinical studies have shown that uPAR can influence the state of phosphorylation and signalling activity of the epidermal growth factor receptor (EGFR) in a ligand-independent manner. The purpose of the study was to evaluate whether plasma soluble intact and cleaved uPAR(I-III) + (II-III) levels could identify a subpopulation of patients with metastatic colorectal cancer (mCRC) where treatment with cetuximab would have a beneficial effect. Plasma samples were available from 453 patients treated in the NORDIC VII study. Patients were randomized between FLOX and FLOX + cetuximab. The levels of uPAR(I-III) 1(II-III) were determined by time-resolved fluorescence immunoassay. We demonstrated that higher baseline plasma uPAR(I-III) 1(II-III) levels were significantly associated with shorter progression-free survival (PFS) (HR51.30, 1.14-1.48, p=0.0001) and overall survival (OS) (HR51.75, 1.52-2.02, p < 0.0001). Multivariate Cox analysis showed that plasma uPAR(I-III) 1(II-III) was an independent biomarker of short OS (HR51.45, 1.20-1.75, p=0.0001). There were no significant interactions between plasma uPAR(I-III) 1(II-III) levels, KRAS mutational status and treatment either PFS (p=0.43) or OS (p=0.095). However, further explorative analyses indicated that patients with low levels of circulating suPAR and a KRAS wild-type tumor have improved effect from treatment with FLOX+cetuximab as compared to patients with KRAS wild-type and high levels of suPAR. These results thus support the preclinical findings and should be further tested in an independent clinical data set.

Place, publisher, year, edition, pages
2015. Vol. 137, no 10, 2470-2477 p.
Keyword [en]
metastatic colorectal cancer, suPAR forms, EGFR inhibition, cetuximab
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:uu:diva-266677DOI: 10.1002/ijc.29476ISI: 000362842600020PubMedID: 25664394OAI: oai:DiVA.org:uu-266677DiVA: diva2:871560
Available from: 2015-11-16 Created: 2015-11-10 Last updated: 2017-12-01Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Authority records BETA

Glimelius, Bengt

Search in DiVA

By author/editor
Glimelius, Bengt
By organisation
Experimental and Clinical Oncology
In the same journal
International Journal of Cancer
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 315 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf